Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

takeda s.r.l. - droguerÍa - brentuximab vedotina - concentrado para solucion para perfusion - 50mg - por vial - - brentuximab vedotina

Unión Europea - español - EMA (European Medicines Agency)

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - agentes antineoplásicos - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

r.h. medica s.a. - solucion para inyeccion - por vial ; albumina humana 20.000000 g; - brentuximab vedotina

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

takeda ecuador cia. ltda. ecuador - brentuximab vedotin 50 mg - polvo para concentrado para soluciÓn para perfusiÓn - cada vial contiene: brentuximab vedotin 50 mg